AIP
NGNE icon

Ameritas Investment Partners’s Neurogene NGNE Stock Holding History

Ameritas Investment Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.7K Hold
1,009
– – ﹤0.01% 2519
2026
Q1 		$20.3K Hold
1,009
– – ﹤0.01% 2589
2025
Q4 		$20.8K Hold
1,009
– – ﹤0.01% 2618
2025
Q3 		$17.5K Hold
1,009
– – ﹤0.01% 2726
2025
Q2 		$15.1K Hold
1,009
– – ﹤0.01% 2791
2025
Q1 		$11.8K Hold
1,009
– – ﹤0.01% 2768
2024
Q4 		$23.1K Hold
1,009
– – ﹤0.01% 2566
2024
Q3 		$42.3K Hold
1,009
– – ﹤0.01% 2290
2024
Q2 		$36.7K Buy
+1,009
New +$35.6K ﹤0.01% 2308
2022
Q2 		– Sell
-131
Closed -$5K – 3178
2022
Q1 		$5K Hold
131
– – ﹤0.01% 2972
2021
Q4 		$13K Hold
131
– – ﹤0.01% 2821
2021
Q3 		$19K Hold
131
– – ﹤0.01% 2733
2021
Q2 		$24K Hold
131
– – ﹤0.01% 2650
2021
Q1 		$32K Hold
131
– – ﹤0.01% 2339
2020
Q4 		$37K Hold
131
– – ﹤0.01% 2158
2020
Q3 		$31K Hold
131
– – ﹤0.01% 2144
2020
Q2 		$44K Buy
+131
New +$34.1K ﹤0.01% 1912

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Ameritas Investment Partners's NGNE Position: Q2 2026 in Review

Ameritas Investment Partners held its Neurogene (NGNE) position steady in Q2 2026 at 1,009 shares worth $31.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2519.

Ameritas Investment Partners first reported a position in NGNE in Q2 2020 and has held it in 17 quarters since. The position peaked at $44K in Q2 2020. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Ameritas Investment Partners held 1,009 shares of Neurogene worth $31.7K as of Q2 2026.
  • Ameritas Investment Partners left its Neurogene share count unchanged in Q2 2026.
  • Neurogene made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2519 holding.
  • Ameritas Investment Partners first reported a position in Neurogene in Q2 2020 and has held it in 17 quarters since.
  • Ameritas Investment Partners's Neurogene position peaked at $44K in Q2 2020.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.